Loading
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
NASDAQHealthcareBiotechnology
Latest quote
$15.01
−$0.18 · -1.18%
Previous close
$15.01
−$0.18 · -1.18%
Pre-market
$15.01
$0.00 · 0.00%
Sep 8, 7:00 AM ET
Regular session · ET · Market data may be delayed.
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Day range
Current $15.01
52-week range
Current $15.01
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
47
Mixed
Risk
66
High Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Day range
Current $15.01
52-week range
Current $15.01
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.62M USD | — | — | — | 4.97K USD |
| Gross profit | −2.62M USD | — | — | — | −4.97K USD |
| Research and development | 202.86M USD | 112.77M USD | 31.8M USD | 42.05M USD | 35.52M USD |
| Selling, general, and administrative | 41.97M USD | 30.32M USD | 22.32M USD | 23.01M USD | 18.05M USD |
| Operating expenses | 242.22M USD | 143.09M USD | 54.12M USD | 65.06M USD | 53.57M USD |
| Interest expense | 7.25M USD | — | — | — | — |
| Depreciation and amortization | 2.62M USD | 1.38M USD | 370.32K USD | 164.78K USD | 4.97K USD |
| Operating income | −244.83M USD | −143.09M USD | −54.12M USD | −65.06M USD | −53.58M USD |
| Net income | −227.32M USD | −118.94M USD | −36.01M USD | −49.97M USD | −53.64M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$50.00
233.11% upsideFunds reporting this stock among their holdings, ordered by reported position size.
T. Rowe Capital Appreciation Equity ETFTCAF3.58M0.04%8.78B USD0.31%$42.83-0.40%
Vanguard Health Care ETFVHT2.42M0.01%20.9B USD0.09%$321.66-0.97%
iShares ESG Aware MSCI USA Small-Cap ETFESML1.33M0.05%2.89B USD0.17%$55.09+0.04%
Nuveen ESG Small-Cap ETFNUSC636.86K0.05%1.3B USD0.31%$51.32-0.02%
Fidelity Nasdaq Composite Index ETFONEQ463.58K—10.75B USD0.21%$104.46-0.29%
Optimize Strategy Index ETFOPTZ378.58K0.14%272.25M USD0.25%$46.2988+1.51%
Fidelity MSCI Health Care Index ETFFHLC316.09K0.01%3.48B USD0.08%$83.14-1.02%
Virtus Biotech Clinical Trials ETFBBC254.92K0.50%50.8M USD0.65%$53.71+0.60%T. Rowe Capital Appreciation Equity ETFTCAFVanguard Health Care ETFVHTiShares ESG Aware MSCI USA Small-Cap ETFESMLNuveen ESG Small-Cap ETFNUSCFidelity Nasdaq Composite Index ETFONEQOptimize Strategy Index ETFOPTZFidelity MSCI Health Care Index ETFFHLCVirtus Biotech Clinical Trials ETFBBCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
